The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.017%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Telecom Plus Up On Strong Earnings, Outlook

Tue, 18th Jun 2019 10:23

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Tuesday.----------FTSE 100 - WINNERS----------Ashtead, up 3.7%. The equipment rentals firm reported strong annual results in financial 2019 buoyed by its Sunbelt business in the US. For the year to April 30, Ashtead recorded pretax profit of GBP1.06 billion, up 23% from GBP862.1 million the year before, as revenue increased 19% to GBP4.50 billion. Its Sunbelt unit saw US total revenue, including new and used equipment, merchandise and consumable sales, increase 20% to USD4.98 billion from USD4.15 billion. The company benefited from Brexit-driven weakness in the pound, which helped increase the value of dollar revenue from the US. Ashtead proposed a final dividend of 33.5 pence, bringing a total payout 40.0 pence, up 21% from 33.0p in financial 2018. The firm added that it continues to look to the medium term with confidence and expects to return up to GBP500 million via share buybacks in 2020 financial year. "This business has been in a sweet spot for a long time thanks to a vibrant US construction market and a structural shift from owning to renting equipment," said AJ Bell's Russ Mould. ----------AstraZeneca, up 1.5%. The Anglo-Swedish drugmaker said Lynparza has been approved in Europe as a first-line maintenance treatment for BRCA-mutated advanced ovarian cancer. The European Commission approved the drug for adults patients with stage three and four ovarian cancer who have a BRCA mutation. BRCA1 and BRCA2 genes help suppress the growth of tumours, and mutations in these genes is associated with an increased risk of cancer. The approval covers "high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer" patients who have responded to 1st-line platinum-based chemotherapy. Lynparza is the only PARP inhibitor approved in the EU for this indication. PARP is an enzyme in cells that helps to repair damaged DNA, and so inhibiting this enzyme prevents cancer cells from repairing themselves.----------FTSE 100 - LOSERS----------Evraz, down 1.5%. The Russian steelmaker was cut to Sell from Neutral by Citigroup.----------InterContinental Hotels Group, down 1.2%. Barclays downgraded the hotel operator to Underweight from Equal Weight. ----------FTSE 250 - WINNERS----------Telecom Plus, up 4.5%. The multi utility services provider said it delivered annual results for financial 2019 in line with expectations. For the year ended March 31, revenue rose 1.5% to GBP804.4 million from GBP792.9 million the year before, and pretax profit increased 4.9% to GBP43.0 million from GBP41.0 million. Adjusted pretax profit increased by 3.7% to GBP56.3 million from GBP54.3 million in 2018. The company said that in the absence of "unforeseen circumstances" it expect adjusted pretax profit for financial 2020 to be between GBP60 million and GBP65 million. Telecom Plus raised its annual dividend 4.0% to 52.0p from 50.0p last year and expects to raise its payout another 10% to 57p in financial 2020. ----------Acacia Mining, up 2.0%. Berenberg raised the gold miner to Hold from Sell. ----------FTSE 250 - LOSERS----------Safestore Holdings, down 1.5%. The self storage company reported a sharp drop in profit in the first half of its financial year due to a considerable reduction in its gain on investment properties. The company company reported a GBP38.2 million pretax profit for the six months to April 30, 53% below its GBP81.9 million profit a year before. This was due to reduced gain on investment properties, coming in at GBP7.9 million for the half compared to a much larger GBP51.8 million gain the year before. On an underlying basis, which excludes investment property gains and other factors, pretax profit rose 7.1% to GBP31.5 million from GBP29.4 million. Revenue rose 5.6% to GBP73.1 million from GBP69.2 million and the company increased its dividend by 7.8% to 5.5 pence from 5.1p.----------OTHER MAIN MARKET AND AIM - WINNERS----------Team17 Group, up 17%. The video game developer said it expects revenue and earnings for 2019 to be ahead of market expectations. Team17 said that both revenue and adjusted earnings before interest, taxes, depreciation and amortisation are set to be ahead of market expectations for the year. In 2018, Team 17 reported adjusted Ebitda of GBP15.3 million on revenue of GBP43.2 million. Since the start of the year, the company said it has continued to experience strong customer traction from both new and established games. Specifically, for the first six months to the end of June, Team17's performance was driven by continued sales momentum, and a solid performances across a range of new releases as well as the recognition of a higher proportion of revenue, which is related to license income.----------OTHER MAIN MARKET AND AIM - LOSERS----------Regency Mines, down 17%. Shares in the natural resource exploration company were down after White Car, in which Regency's subsidiary EsTeq is invested, announced it entered voluntary liquidation. White Car operates Tesla rental car services out of Heathrow and several UK locations. In December 2017, Regency Mines said that EsTeq had invested GB200,000 in White Car, and that it planned to make a further GBP200,000 investment in February 2018, which would give EsTeq a 5.8% stake. EsTeq's investment in White Car was held at no value in Regency's most recent interim accounts for the period to the end of December, published on March 29. Regency said that it is continuing a strategic review of its operations, alongside the formation of a revised board of directors.----------

More News
8 Feb 2024 12:08

LONDON MARKET MIDDAY: DS Smith surges on takeover approach from Mondi

(Alliance News) - Stock prices in London were mixed at midday Thursday, as markets struggled to find direction amid a mixed wave of corporate updates and earnings.

Read more
8 Feb 2024 08:59

LONDON MARKET OPEN: Unilever up on buyback; BAT ups dividend

(Alliance News) - THE FTSE 100 in London opened slightly higher on Thursday, with earnings from British American Tobacco and Unilever boosting the index.

Read more
8 Feb 2024 08:44

TOP NEWS: AstraZeneca confident after 2023 profit more than doubles

(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.

Read more
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more
2 Feb 2024 06:22

TOP NEWS: US sends drugmakers initial offers in Medicare price talks

(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Read more
1 Feb 2024 15:52

UK earnings, trading statements calendar - next 7 days

Friday 2 February 
YouGov PLCTrading Statement
Monday 5 February 
Home REIT PLCTrading Statement
Porvair PLCFull Year Results
Trident Royalties PLCTrading Statement
Vodafone Group PLCTrading Statement
Tuesday 6 February 
Alumasc Group PLCHalf Year Results
BP PLCFull Year Results
Filtronic PLCHalf Year Results
Mattioli Woods PLCHalf Year Results
Renishaw PLCHalf Year Results
Virgin Money UK PLCTrading Statement
Wednesday 7 February 
Ashmore Group PLCHalf Year Results
Barratt Developments PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Phoenix Spree Deutschland LtdTrading Statement
PZ Cussons PLCHalf Year Results
Smurfit Kappa Group PLCFull Year Results
UK Commercial Property REIT LtdTrading Statement
Thursday 8 February 
Anglo American PLCTrading Statement
AstraZeneca PLCFull Year Results
British American Tobacco PLCFull Year Results
Compass Group PLCTrading Statement
Redrow PLCHalf Year Results
SSE PLCTrading Statement
Unilever PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.